Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.
Stephen Ziegler, PhD, JD, describes the various alternative and complementary treatments available for palliative care and pain management in patients with rheumatic disease.
Elizabeth Volkmann, MD, MS, discusses systemic sclerosis associated interstitial lung disease and how to evaluate subclinical, clinical, and progressive disease for the best outcome.
A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.
A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.
A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.
Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.
Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.
A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.
Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.
While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.
Discussing the importance of implementing a multidisciplinary team when treating conditions that put patients at a predisposition for comorbidities with Rania Al Asmar, MBBS, of Marshall University.
Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.